HRTX Q4 2018 Earnings — Heron Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

HRTXHeron Therapeutics, Inc.

$153M

Q4 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$29M+186.9% YoY

Gross Profit

$17M59.9% margin

Operating Income

-$51M-177.9% margin

Net Income

-$50M-171.8% margin

EPS (Diluted)

$-0.63

QoQ Revenue Growth

+45.8%

Cash Flow

Operating Cash Flow

-$33M

Free Cash Flow

-$37M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$462M

Total Liabilities

$92M

Stockholders' Equity

$370M

Cash & Equivalents

$32M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$29M	$10M	+186.9%
Gross Profit	$17M	$9M	+98.2%
Operating Income	-$51M	-$62M	+17.1%
Net Income	-$50M	-$62M	+20.7%